Egyptian International Pharmaceutical Industries Valuation
Is PHAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PHAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PHAR (EGP44.98) is trading above our estimate of fair value (EGP40.62)
Significantly Below Fair Value: PHAR is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PHAR?
Other financial metrics that can be useful for relative valuation.
| What is PHAR's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ج.م6.69b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | 8.3x |
| PEG Ratio | 0.6x |
Price to Earnings Ratio vs Peers
How does PHAR's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17.1x | ||
RMDA Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E | 16.6x | 27.1% | ج.م3.7b |
BIOC GlaxoSmithKlineE | 36.5x | n/a | ج.م2.7b |
OCPH October PharmaE | 8x | n/a | ج.م1.2b |
AXPH Alexandria For Pharmaceuticals & Chemical Industries | 7.5x | n/a | ج.م1.1b |
PHAR Egyptian International Pharmaceutical Industries | 8.1x | 14.2% | ج.م6.7b |
Price-To-Earnings vs Peers: PHAR is good value based on its Price-To-Earnings Ratio (8.1x) compared to the peer average (17.1x).
Price to Earnings Ratio vs Industry
How does PHAR's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?
Price-To-Earnings vs Industry: PHAR is good value based on its Price-To-Earnings Ratio (8.1x) compared to the Global Pharmaceuticals industry average (24.1x).
Price to Earnings Ratio vs Fair Ratio
What is PHAR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 8.1x |
| Fair PE Ratio | 11x |
Price-To-Earnings vs Fair Ratio: PHAR is good value based on its Price-To-Earnings Ratio (8.1x) compared to the estimated Fair Price-To-Earnings Ratio (11x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ج.م44.98 | ج.م72.20 +60.5% | 7.8% | ج.م79.60 | ج.م66.00 | n/a | 3 |
| Apr ’25 | ج.م44.14 | ج.م72.20 +63.6% | 7.8% | ج.م79.60 | ج.م66.00 | n/a | 3 |
| Mar ’25 | ج.م48.00 | ج.م72.20 +50.4% | 7.8% | ج.م79.60 | ج.م66.00 | n/a | 3 |
| Feb ’25 | ج.م40.98 | ج.م61.87 +51.0% | 26.6% | ج.م79.60 | ج.م40.00 | n/a | 3 |
| Jan ’25 | ج.م36.50 | ج.م61.87 +69.5% | 26.6% | ج.م79.60 | ج.م40.00 | n/a | 3 |
| Dec ’24 | ج.م40.48 | ج.م61.87 +52.8% | 26.6% | ج.م79.60 | ج.م40.00 | n/a | 3 |
| Nov ’24 | ج.م38.60 | ج.م61.87 +60.3% | 26.6% | ج.م79.60 | ج.م40.00 | n/a | 3 |
| Oct ’24 | ج.م33.91 | ج.م58.90 +73.7% | 25.7% | ج.م79.60 | ج.م40.00 | n/a | 4 |
| Sep ’24 | ج.م31.79 | ج.م58.90 +85.3% | 25.7% | ج.م79.60 | ج.م40.00 | n/a | 4 |
| Aug ’24 | ج.م25.99 | ج.م60.53 +132.9% | 22.3% | ج.م79.60 | ج.م50.00 | n/a | 3 |
| Jul ’24 | ج.م27.00 | ج.م60.53 +124.2% | 22.3% | ج.م79.60 | ج.م50.00 | n/a | 3 |
| Jun ’24 | ج.م26.11 | ج.م60.53 +131.8% | 22.3% | ج.م79.60 | ج.م50.00 | n/a | 3 |
| May ’24 | ج.م33.48 | ج.م60.53 +80.8% | 22.3% | ج.م79.60 | ج.م50.00 | n/a | 3 |
| Apr ’24 | ج.م33.65 | ج.م60.53 +79.9% | 22.3% | ج.م79.60 | ج.م50.00 | ج.م44.14 | 3 |
| Mar ’24 | ج.م35.18 | ج.م65.80 +87.0% | 21.0% | ج.م79.60 | ج.م52.00 | ج.م48.00 | 2 |
| Feb ’24 | ج.م38.47 | ج.م65.80 +71.0% | 21.0% | ج.م79.60 | ج.م52.00 | ج.م40.98 | 2 |
| Jan ’24 | ج.م36.51 | ج.م63.87 +74.9% | 18.2% | ج.م79.60 | ج.م52.00 | ج.م36.50 | 3 |
| Dec ’23 | ج.م34.45 | ج.م63.87 +85.4% | 18.2% | ج.م79.60 | ج.م52.00 | ج.م40.48 | 3 |
| Nov ’23 | ج.م31.90 | ج.م71.53 +124.2% | 11.7% | ج.م79.60 | ج.م60.00 | ج.م38.60 | 3 |
| Oct ’23 | ج.م30.40 | ج.م71.53 +135.3% | 11.7% | ج.م79.60 | ج.م60.00 | ج.م33.91 | 3 |
| Sep ’23 | ج.م31.53 | ج.م71.53 +126.9% | 11.7% | ج.م79.60 | ج.م60.00 | ج.م31.79 | 3 |
| Aug ’23 | ج.م29.89 | ج.م67.98 +127.4% | 14.0% | ج.م79.60 | ج.م57.30 | ج.م25.99 | 4 |
| Jul ’23 | ج.م30.44 | ج.م67.98 +123.3% | 14.0% | ج.م79.60 | ج.م57.30 | ج.م27.00 | 4 |
| Jun ’23 | ج.م30.73 | ج.م67.98 +121.2% | 14.0% | ج.م79.60 | ج.م57.30 | ج.م26.11 | 4 |
| May ’23 | ج.م34.02 | ج.م70.48 +107.2% | 11.8% | ج.م79.60 | ج.م57.30 | ج.م33.48 | 4 |
| Apr ’23 | ج.م38.32 | ج.م70.48 +83.9% | 11.8% | ج.م79.60 | ج.م57.30 | ج.م33.65 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.